ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma , that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL and conditional marketing authorization by the European Commission in October 2012 for relapsed or ... (more)
http://eon.businesswire.com/news/eon/20130621005125/en/Seattle-Genetics-Highlights-ADCETRIS%C2%AE-Brentuximab-Vedotin-Clinical
http://eon.businesswire.com/news/eon/20130621005125/en/Seattle-Genetics-Highlights-ADCETRIS%C2%AE-Brentuximab-Vedotin-Clinical
No comments:
Post a Comment